Business Context and Reporting Period
This Form 8-K Current Report was filed by Dyadic International, Inc. on March 18, 2021. The filing discloses the entry into a Material Definitive Agreement regarding the advancement of the Company's SARS-CoV-2 vaccine candidate.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a contractual agreement rather than periodic financial performance.
Material Changes and Agreements
- Master Services Agreement (MSA): On March 18, 2021, Dyadic International (USA), Inc. entered into an MSA with CR2O B.V.
- Scope of Services: CR2O is engaged to oversee and perform pre-clinical and clinical trial services for the Company's C1 produced SARS-CoV-2 receptor binding domain (RBD) vaccine candidate.
- Work Order 01: Specifically covers pre-clinical trial services, including a toxicology study.
- Term: The initial term of the MSA is five years from the Effective Date.
- Strategic Goal: These services support the Company's move toward an anticipated Phase 1 clinical trial.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the partnership to advance the vaccine candidate. The filing references a press release (Exhibit 99.1) for further details. No specific financial guidance, risk factors, or contingencies are detailed within the text of this 8-K, other than the inherent risks associated with clinical trial development.
Key Facts for Investor Verification
- Verify the specific financial obligations and payment terms within the redacted Master Services Agreement (Exhibit 10.1).
- Confirm the timeline and milestones for the toxicology study and the anticipated Phase 1 clinical trial.
- Review the full press release (Exhibit 99.1) for additional context on the partnership with CR2O B.V.
- Monitor subsequent filings for updates on the progress of the pre-clinical and clinical trials.